Kamgios Capsule 10 mg (Mavacamten)

Adult dose

The recommended starting dose of this drug is 5 mg orally once daily, with or without food. Swallow this drug whole with water. Do not open, crush, or chew the capsule. Assess the patient's initial clinical response 4 weeks after starting treatment. If the Valsalva LVOT gradient is < 20 mmHg, reduce the dose to 2.5 mg once daily. Otherwise, maintain the dose at 5 mg once daily. Subsequent visits should take place 8 and 12 weeks after starting treatment, with dose adjustments as needed.

This drug may reduce the function of the left ventricle of the heart to pump blood, potentially causing heart failure. Therefore, heart function should be tested before taking this drug, and the heart’s condition should be monitored regularly during treatment. If heart function is below a certain standard, this drug should not be taken, and if heart function worsens or symptoms of heart failure appear during treatment, it should be discontinued immediately. This drug must not be used in pregnant women, as it may be harmful to the fetus. Women of childbearing potential must confirm whether they are pregnant before using this drug and employ effective contraceptive methods during treatment and for at least 4 months after discontinuation. Patients with allergies to this drug or with certain liver and kidney dysfunctions, as well as those taking specific medications, should not use this drug. There are many drug interactions, and taking this drug with medications that affect hepatic enzyme metabolism may change the drug’s effects or increase the risk of side effects. Therefore, all medications currently taken must be disclosed to the doctor, and adjustments may be necessary. Common side effects include dizziness and headaches, and serious heart-related side effects may occur rarely. If severe dizziness occurs during treatment, driving or operating machinery should be avoided. Overdosage of this drug may severely impair heart function, so overdose should be avoided, and if overdose is suspected, appropriate medical treatment should be sought immediately. Finally, this drug should only be used under the guidance of a physician with expertise in cardiology, and patients should not stop or change the dosage on their own.

• Dizziness
• headache
• stress-induced cardiomyopathy
• syncope
• atrial fibrillation
• nasopharyngitis
• back pain
• cough
• shortness of breath
• fatigue

This drug may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is best to keep the storage temperature between 1 degree and 30 degrees Celsius at room temperature.

Appearance

This drug is a hard capsule that is opaque pink on the upper part and opaque white on the lower part, filled with a white to off-white powder, with "10 mg" printed on the upper part and "Mava" on the lower part.

Package unit

Blister - 28 capsules/box